Enanta Pharmaceuticals (ENTA) to Release Earnings on Wednesday

Enanta Pharmaceuticals (NASDAQ:ENTA) is projected to announce its earnings results before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($1.16) per share and revenue of $17.25 million for the quarter.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The company had revenue of $14.60 million for the quarter, compared to the consensus estimate of $17.99 million. During the same period last year, the business earned ($1.33) EPS. The firm’s quarterly revenue was down 22.8% on a year-over-year basis. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Stock Up 1.2 %

ENTA stock opened at $5.17 on Tuesday. The business has a 50 day moving average of $6.31 and a 200 day moving average of $10.02. Enanta Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $17.80. The firm has a market cap of $110.28 million, a PE ratio of -0.94 and a beta of 0.54.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ENTA shares. JMP Securities restated a “market outperform” rating and issued a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. HC Wainwright reduced their target price on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, December 24th. Finally, Robert W. Baird reduced their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Insiders Place Their Bets

In other news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares in the company, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 13.89% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.